Clinical Briefs-By Louis Kuritzky, MD
Clinical Briefs-By Louis Kuritzky, MD
Predicting LVH in Hypertensive Men
The presence of left ventricular hypertrophy (LVH) in patients with hypertension is a marker of high risk. The same is true of proteinuria (PRO). JNC VI suggests intensified treatment in persons with manifest target organ damage, such as proteinuria and LVH. The most accurate method for determination of LVH is echocardiography; the most accurate method for determination of proteinuria (or microalbuminuria) is 24-hour urine quantitation. Both measurement tools are cumbersome, and echo-cardiography is prohibitively expensive. Whether detection of proteinuria by a spot urine specimen might correlate with LVH has not been prospectively studied and is the subject of this report. Subjects were previously untreated hypertensive African-American men (n = 109). Each subject underwent echocardiography and a single afternoon random urine albumin.
There was a significant correlation between LVH and PRO, independent of other variables related to left ventricular mass or albuminuria. The magnitude of the correlation was similar to that of systolic BP and LVH.
Post et al conclude that obtaining a single random urine for protein is an important predictor of LVH. Since the presence of LVH is an ominous predictor for hypertensive patients, and only a few patients with hypertension actually receive echocardiography due to its expense, the presence of increased protein excretion on a random afternoon sample might be considered a suitable surrogate marker for increased likelihood of LVH.
Post WS, et al. Am J Hypertens 2000; 13:1168-1172.
Patients’ Knowledge of End of Life Options
End of life (eol) decisions may include such issues as the right to refuse or withdraw life-sustaining treatment, advance directives, legalized physician-assisted suicide, and the double effect (i.e., the legality of administering pain medication that might have the additional effect of hastening death). Despite the widespread familiarity of clinicians with such issues, it remains equally pertinent that the public at large be conversant and informed about such issues. That our populace may be inadequately informed is echoed by results of a recent national poll in which more than one-third of persons were not familiar with the terms "hospice" or "palliative care." This report specifically assessed outpatient adults’ (n = 1000) knowledge in four primary areas: refusal and withdrawal of life-saving treatments, physician-assisted suicide, active euthanasia, and the doctrine of double effect.
Subjects were presented with clinical vignettes, such as a patient with terminal cancer, and asked whether the patient had a legal right to refuse potentially curative treatment, IV fluids, or feeding tube. Also, they were queried as to whether the physician could legally turn off a ventilator, inject medication to hasten death, or prescribe a medication that the patient would be enabled to end life if so desired.
Most persons did understand that (in Oregon), patients could refuse life-saving treatment. Less than half understood that patients could withdraw life-sustaining treatment. Only about one-quarter of persons could properly identify assisted suicide as a legal option.
To maximize the benefits of EOL options, the public must be adequately informed of these choices. Even in Oregon, where one would anticipate that knowledge of such issues might be higher than other locales due to recent intense media publicity, there remains substantial room for improvement in public knowledge of EOL options.
Silveira MJ, et al. JAMA 2000;284: 2483-2488.
PLA2 as A Predictor of CHD
The west of scotland coronary Prevention Study evaluated 6595 men with LDL 174-232 mg/dL without history of myocardial infarction treated with pravastatin or placebo. Evolution of knowledge about atherosclerosis and its consequences has focused attention upon the role of plaque susceptibility and stabilization as crucial factors determining manifest vascular end points. Phospholipase A2 (PLA2) is an enzyme that may affect atherosclerosis, since it is found in the media of arteries, and is believed to play a role in LDL modification, potentially inducing atherogenic changes in the vascular wall. Using the West of Scotland Study population, Packard et al measured PLA2 at baseline.
Increased levels of PLA2 were independently associated with a significantly greater risk of the composite end point of nonfatal MI, cardiac death, or revascularization. The risk at the highest quintile was about double that for the lowest. The relationship of PLA2 levels in the West of Scotland trial was equally prominent in recipients of pravastatin as it was in placebo subjects. Packard et al conclude that PLA2 is a potential risk factor that may directly affect atherosclerosis.
Packard CJ, et al. N Engl J Med 2000;343:1148-1155.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.